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Abstract 
In recent years, the use of Traditional Chinese Medicines (TCMs) has 
aroused a lot of interest in biomedical research and for treatment of different kinds 
of disorders. Several TCMs were tested in our lab. Among them. Agrimony was 、 
found to display effects on the liver in the preliminary study; thus, it was selected 
in this thesis work. 
Agrimony is the common name for Agrimonia pilosa Ledeb. Nakai. It was 
widely used in combination with other herbs for treatment of liver disorders, 
including liver cancer. Hepatocellular carcinoma (HCC) is the fourth most 
common cancer in the world. There are about 500,000-1,000,000 new HCC cases 
per year. It can result from a multi-factorial and multi-stage process. 
The effects of Agrimonia pilosa (AP) on hepatocarcinogenesis were 
investigated in both in vivo and in vitro models. Hepatocarcinogenesis was 
initiated by diethylnitrosamine (DEN) and further promoted by carbon 
tetrachloride (CCI4) in male Fischer 344 rats. After AP treatment, pathological 
changes in the rats were evaluated by Hematoxylin and Eosin (H & E) staining of 
the liver sections and analysis of GST-P positive foci. The enzyme activities of 
cyclooxygenase-2 (COX-2), CYP2E1 and GST were measured. The mRNA 
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expression of GST-P and COX-2 genes were analyzed by RT-PCR. Effects of AP 
on a hepatoma cell line H4IIE were also evaluated by Neutral Red assay, DNA 
fragmentation analysis and flow cytometry. 
In the DEN-CCU-treated rats, a decrease in body weight and relative liver 
weight and shrinkage of the livers were recorded. H & E staining showed that the 
DEN-CCU-induced damage to the liver parenchyma was reduced after AP 
treatment Immunohistochemical study of GST-P foci and RT-PCR analysis of 
GST-P gene demonstrated an inhibitory effect of AP on this preneoplastic marker 
which is believed to be associated with hepatocarcinogenesis. In addition, AP 
decreased COX-2 activity and regulated its gene expression in the liver when 
co-administered with DEN-CCI4. Furthermore, co-administration and 
post-administration of AP with DEN-CCU showed different effects on CYP2E1 
activity, whereas GST activity was increased by AP treatment. In H4IIE cells, AP 
inhibited cell viability in a dose-dependent manner as observed in Neutral Red 
assay. DNA fragmentation analysis revealed no DNA laddering formation. Flow 
cytometry showed an arrest of cell cycle at G2/M phase during AP treatment. 
The current results suggest AP could prevent hepatocarcinogenesis. This is 
consistent with previous studies that AP exhibits anti-tumor effects on 
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transplantable rodent tumors. Its biologic actions may involve regulating the 
immune system in the early stages of hepatocarcinogenesis and modulating 
specific enzymes which are responsible for detoxification and bioactivation of 
carcinogens. The arrest of H4IIE cells at G2/M phase suggests the effects of AP 
on cell proliferation may be attributed to its regulation on cell cycle but not 
induction of apoptosis. However，it is unlikely to draw a precise conclusion from 
our limited experiments on how AP contributes to the anti-cancer properties. More 









































I would like to express my deepest gratitude to my supervisor, Prof. Ho Wing 
Shing, for his patient guidance, advice and support leading me to accomplish my 
postgraduate study. His kind and sincere supervision during my study is most 
unforgettable. 
I would like to thank Prof. W. Y. Chan and the Department of Anatomy for 
providing the facilities for the histological analysis. 
Gratitude also goes to my lab mates, for their kind help and valuable 
discussions they shared with me through my study. 
Finally, I mush thank my family for their love, care, and never-ending 
encouragement. 
vi 
List of Abbreviations 
Ap A g r i m o n i a p i losa 
carbon te t rach lo r ide 
CDNB ch lo ro -2 ,4 -d in i t robenzene 
Qg ca l f serum 
CYP cytochrome P-450 enzymes 
d a b 3，3,-diaminobenzidine 
d e n d ie thy ln i t rosamine 
D e p c d ie thy l pyrocarbonate 
了 d i t h io th re i t o l 
e th id ium bromide 
EDTA ethylenediaminetetraacetic acid 
p g g fetal bovine serum 
Q^H Glutathione 
GST glutathione S-transferase 
H & E hematoxyl in and eosin 
H c c hepatocel lular carcinoma 
IARC International Agency for Research in Cancer 
m e m Mod i f i ed Eagle Medium 
PBS Phosphate Buffered Saline 
PI prop id ium iodide 
PSN penic i l l in , streptomycin and neomycin 
TCM Tradit ional Chinese Medicine 
vii 
TMPD N,N,N' ,N ' - te t ramethylphenylenediamine 
X M E xenobiot ic metabol is ing enzyme 
viii 
List of tables and figures 
Table 2.1 35 Figure 3.14 65 
Table 3.1 45 Figure 3.15 66 
Table 3.2 62 Figure 3.16 67 
Figure 1.1 2 Figure 3.17 68 
Figure 2.1 15 Figure 3.18 69 
Figure 3.19 70 
Figure 2.2 19 
Figure 3.20 71 
Figure 3.1 47 
Figure 3.21 73 
Figure 3.2 48 
Figure 3.22 75 
Figure 3.3 49 
Figure 3.4 52 Figure 3.23 77 
Figure 3.5 53 Figure 3.24 79 
Figure 3.6 54 Figure 3.25 81 
Figure 3.7 55 Figure 3.26 83 
Figure 3.8 56 Figure 3.27 84 
Figure 3.9 57 Figure 3.28 85 
Figure 3.10 58 Figure 3.29 86 
Figure 3.11 59 Figure 3.30 87 
Figure 3.12 63 Figure 3.31 89 






List of Abbreviations vii 
List of tables and figures ix 
Content ^ 
Chapter 1: Introduction 1 
1.1 Traditional Chinese Medicine: Agr imony 1 
1.2 Hepatocellular carcinoma (HCC) and its risk factors 4 
1.3 Basic concepts relevant to cancer prevention 6 
1.3.1 Multistage process o f carcinogenesis 6 
1.3.2 Chemical carcinogenesis 7 
1.3.3 Possible chemopreventive strategies 8 
1.3.4 Phase I and phase I I systems in chemical carcinogenesis... 10 
Chapter 2 Materials and methods 12 
2.1 Preparation of aqueous extract of Agrimonia pilosa 12 
2.2 In vivo study 13 
2.2.1 Animal model for hepatocarcinogenesis 13 
X 
2.2.1.1 Chemical carcinogens 13 
2.2.1.2 Animals 16 
2.2.1.3 An imal treatment and sacrifice 17 
2.2.2 Histological and immunohistochemical study 20 
2.2.3 Preparation o f l iver homogenates and microsomes from rat23 
2.2.4 Determination o f protein concentration 24 
2.2.5 COX-2 Act iv i ty Assay 25 
2.2.6 Cytochrome P450 2E1 Assay 26 
2.2.7 Spectrophotometric Assay for GST 28 
2.2.8 Isolation o f total R N A from liver homogenate 29 
2.2.9 Semi-quantitative RT-PCR analysis 32 
2.3 In vitro study 36 
2.3.1 Cell cultures 36 
2.3.2 Cytotoxicity assay — Neutral Red Assay 38 
2.3.3 Cell cycle distribution analysis by f low cytometry 39 
2.3.4 D N A fragmentation 40 
Chapter 3 Results 43 
3.1 In vivo study 43 
3.1.1 Body weight and relative liver weight 43 
3.1.2 Gross Morphological changes 46 




3.1.4 Effect o f AP on DEN-CCU-induced GST-P positive foci 
formation and GST-P m R N A expression 60 
3.1.5 Effects o f AP on COX-2 72 
3.1.6 Effects o f AP on phase I and phase I I enzymes 76 
」 80 
3.2 In vitro study 
3.2.1 Effects o f AP on proliferation o f H4 I IE cells detected by 
80 
Neutral Red Assay 
3.2.2 Assessment o f cell cycle distribution by flow cytometry . " .82 
oo 
3.2.3 D N A Fragmentation Assay o 
90 
Chapter 4 Discussion 
, 90 
4.1 In vivo study 
4.1.1 Morphological changes during the induction o f 
. . 90 
hepatocarcinogenesis 
4.1.2 Effects o f AP on GST-P foci and its m R N A 91 
4.1.3 Effects o f AP on COX-2 enzyme activity and m R N A 
. 93 
expression 
4.1.4 Modulat ion effects o f AP on CYP2E1 and GST enzyme 
. 95 
activity 




n , 102 
References 
xiii 
Chapter 1: Introduction 
1.1 Traditional Chinese Medicine: Agrimony 
Traditional Chinese medicine (TCM) is a well-recognized system of 
medical knowledge based on observation, experiments, experience and 
some basic theories that evolved from the findings (Li, 1974). The 
usefulness of certain herbs has been known for thousands of years. Recently, 
TCM has aroused a lot of interest, as herbal medicine becomes a widely 
acceptable way of alternative treatment of cancers and other common 
disease, because of the less drug resistance and fewer side effects when 
compared with Western treatments. 
Up to now, some Chinese herbal medicines traditionally used by 
indigenous healers have been shown to enhance liver functions and cure 
diseases of the liver. The earlier studies in our lab showed that a traditional 
herbal medicine Agrimony exhibited anti-cancer properties. Thus, 
Agrimony was selected used in this study. 
The earliest record of Agrimony in China is from Bencao Tujing (《本 
草圖,經》），in which its traditional name is Xianhecao (Figure 1.1). 
Agrimony is the common name for Herba Agrimoniae (family Rosaceae), 
also with the botanical name, Agrimonia pilosa Ledeb. Naked. 
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The whole plant of Agrimonia pilosa 
Dried plant for use 
(Adopted from http://members.shawxa/wspab/medicine/xiaiihecao.html) 
Figure 1.1 Plant of Agrimonia pilosa 
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Agrimony is found in east Europe, Russia, and East Asia, including 
China and Japan. This perennial plant grows to about 0.6 m high. It is in 
flower from June to August, and the seeds ripen from August to September. 
The plant is reaped when the stems and leaves are exuberant in summer and 
autumn. It is weeded, dried in the sun and cut into lengths for use. 
Agrimony has the bitter taste and the astringent and neutral properties. 
Modem research has revealed the major components of this herb, which 
includes agrimoniin, agrimophol, agrimonolide, agrimonol, tannin, volatile 
oil, vitamins C and K, etc. The Meridians of this herb is through lung, liver 
and spleen. Its major functions were reported to stop bleeding, relieve 
dysentery, and k i l l parasites (Chen M. et al., 2000). 
According to the literature in Traditional Chinese Medicine, Agrimony 
was widely used in combination with other herbs for treatment of various 
cancers, including liver cancer. Recently, its anti-tumor activity has been 
proved by some scientific experiments. An aqueous extract of Agrimonia 
pilosa exhibited varying degrees of inhibitory effects on numerous 
transplantable experimental tumor lines (Tang et al., 1981). Agrimoniin, 
tannin from Agrimonia pilosa Ledeb, was found to reject the MM2 cell (i.p.) 
induced tumor growth in the mice and could prolong the life span of mice 
bearing MM2. Agrimoniin also inhibited the growth of MH134 and Meth-A 
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solid type tumors and showed strong cytotoxicity on MM2 cells in vitro 
(Miyamoto K. et al., 1987). 
1.2 Hepatocellular carcinoma (HCC) and its risk factors 
Liver cancer (International classification of Disease 155, 9th Revision) 
refers to the disease in which liver cells become abnormal, grow out of 
control, and finally form cancerous tumors. Most primary liver cancers 
begin in hepatocytes (liver cells). This type of liver cancer is called 
hepatocellular carcinoma (HCC). 
HCC is the fourth most common cancer in the world (Parkin D.M. et 
al., 1997). There are about 500,000-1,000,000 new HCC cases per year 
(Hubert B. 1994). In Asia, the incidence of HCC is about 10-20 per 100,000 
population in contrast to that of 1-3 per 100,000 population in Australia, 
Europe and North America (Higginson J., 1963; Wu P.C. 1983). HCC is the 
second most common cancer among males and the seventh among females 
in Hong Kong (Hong Kong Cancer Registry 1989 annual statistical report). 
Generally, there are environmental and genetic reasons as risk factors 
for HCC. 
Infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) is 
believed to be one major risk factor in the environment (Benvegnu L. et al., 
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1994; Ikeda K. et al., 1993; Chiaramonte M. et al., 1999; Shiota G. et al., 
1999). HCC can develop late in the course of viral infection, especially of 
chronic HCV infection, after the development of cirrhosis (Kiyosawa K. et 
al., 1990). HCV carriers demonstrate higher rates of developing HCC than 
HBV carriers (Takano S. et al., 1995); the incidence of HCC in HCV 
carriers is 4.2-fold higher than in HBV carriers, and it is 572-fold higher 
than in normal individuals (Omata M. et al., 1994). 
Exposure to chemical carcinogens is another major risk in the 
environment. Numerous chemical agents have been identified to contribute 
to HCC, such as aflatoxin, nitrosamines, vinyl chloride, peroxisome 
proliferators etc. (Brechot C.，1994). Most of these agents either directly or 
indirectly induce modifications in DNA, or act as promoters that facilitate 
the proliferation of hepatocytes and the fixation of DNA lesions. A 
well-studied case is aflatoxin, a harmfUl substance formed by Aspergillus 
flavus, which is a frequent contaminant in peanuts, com, and other nuts and 
grains (Wogan G.N., 1999; L iu J. et al, 2001) 
In addition, individuals are known to differ in their genetical 
susceptibility to carcinogenesis (Vineis P., 1997)，including mutations in 
oncogenes and tumor suppressor genes (Vainio H. et al., 1996; Spivack S.D. 
et al., 1997). Variability in the genome occurs at the levels of genes 
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(mutation/deletion/insertion/DNA adduct) or chromosomes (SCE，sister 
chromatid exchange). Some of these changes may be associated with 
inter-individual differences in susceptibility to toxicity and the tumor 
initiation (Inada T. et al., 1995; Klaassen C.D., 1998). 
1.3 Basic concepts relevant to cancer prevention 
1.3.1 Multistage process of carcinogenesis 
The view of carcinogenesis as consisting of three biological stages, 
initiation, promotion and progression provides a very useful conceptual 
framework for understanding cancer development and designing 
experiments (Dragan Y.R et al., 1993). Carcinogenesis often proceeds 
through multiple discernible but often overlapping stages (Foulds L., 1969). 
This multistage process begins when a carcinogen causes genetic changes 
or damages the DNA in a normal cell. This makes the cell more vulnerable 
to other genetic changes. This stage is called initiation. I f the initiated cell is 
further exposed to an agent that enhances its growth and replication into a 
larger mass, the process stepped into the next stage of carcinogenesis, 
promotion. Then additional genetic and epigenetic events can take place to 
confer the necessary phenotypes of invasiveness, and metastasis, resulting 
in transforming the cells into malignant tumor, these are the transformation 
and progression stages. When a tumor forms, it has all of the same basic 
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needs as normal cells. Because the tumor cells are genetically damaged, 
they are inefficient and rob normal cells o f important oxygen and nutrients. 
In addition, a malignant tumor grows uncontrollably and can eventually 
interfere wi th the function of vital organs, such as the liver (Liver Cancer 
Network, Presented by Allegheny General Hospital, West Perm Allegheny 
Health System, 2002). Hepatic carcinogenesis (hepatocarcinogenesis) like 
other cancers, is a multi-factorial and multi-stage process (Farber E., 1984; 
Brechot C.，1994; Johnson RJ” 1996; Alberts S.R. et al., 1991; Biden K. et 
al., 1997; Ho S. et al., 1996; Teeter L.D. et al； 1993). 
1.3.2 Chemical carcinogenesis 
The International Agency for Research in Cancer ( lARC) has defined 
chemical carcinogenesis as "the induction by chemicals of neoplasm that 
are not usually observed, the earlier induction by chemicals of neoplasm 
that are usually observed, and the induction by chemicals of more 
neoplasms than are usually found" ( lARC, 1982). 
Chemical carcinogens can be classified into two categories, genotoxic 
and nongenotoxic. Genotoxic carcinogens, or their electrophilic metabolites, 
bind covalently to DNA and cause base substitutions, base deletions or 
additions, and strand scissions; they thus are mutagens. Highly reactive 
forms of oxygen and metabolites of nitrogen oxide that are formed 
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endogenously can also cause DNA damage. Several nongenotoxic agents， 
including phorbol ester tumor promoters, diacylglycerol, several hormones, 
and several halogenated organic compounds can also enhance multistage 
carcinogenesis by complex mechanisms (Weinstein I.B., 1991; Weinstein 
LB. et al., 1995a; Weinstein LB. et al., 1995b) 
1.3.3 Possible chemopreventive strategies 
Corresponding to the complexity of the multistage process of 
carcinogenesis, chemopreventive agents may inhibit the effects of either 
genotoxic or nongenotoxic agents and chemopreventive strategies are 
possible at different levels (Kelloff GJ., 1999; Lippman S.M. et al., 1998; 
Wattenberg L.W., 1998; Hong W.K. et al； 1997; Kel loff G.J. et al., 1997). 
Chemopreventive agents can be classified into two major groups: 
blocking agents and suppressing agents (Wattenberg L.W., 1992a; 
Wattenberg L.W., 1992b; Wattenberg L.W. et al., 1992c). Some 
compounds may have both effects. 
Blocking agents prevent cancer-producing compounds from reaching 
or reacting with critical target sites in the tissues (Wattenberg L.W.，1996). 
They are the chemicals that trap ultimate carcinogens, preventing their 
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interactions with D N A (e.g., ellagic acid or flavonoids, in fruits and 
vegetables) (Alberts D.S. et al., 1999) 
There are three mechanisms by which blocking agents exert their 
effects. They can prevent carcinogen activation, enhance detoxification of 
carcinogenic agents, or trap cancer-producing compounds prior to their 
reaching or reacting with critical target sites in tissues. (Wattenberg L.W., 
1996) 
Suppressing agents act after attack by carcinogens. These compounds 
prevent the evolution of the neoplastic process in cells already altered by 
carcinogenic stimuli, which appear to inhibit the carcinogenic process after 
initiation. (Wattenberg L.W., 1992a; Wattenberg L.W., 1993). They include 
substances such as antioxidants present in fruits and vegetables that 
scavenge free radicals (e.g., selenium and 6-carotene), as well as COX and 
lipoxygenase inhibitors. (Alberts D.S. et aL, 1999) 
There are several means known by which suppressing agents produce 
their effects. Some act by producing differentiation, others are directed 
specifically at counteracting the consequences of genotoxic events, in 
particular, oncogene activation, and a third group produces selective 
inhibition of proliferation of potentially malignant cells (Wattenberg L.W., 
1993; Wattenberg L.W., 1996). There are many other suppressing agents 
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that do not fit into any of the above three categories (Wattenberg L.W. et al., 
1992c; Wattenberg L.W., 1993; Wattenberg L.W., 1996). 
1.3.4 Phase I and phase II systems in chemical carcinogenesis 
The metabolic function of the liver are numerous and intricate. One of 
the most important roles of the liver is to remove or excrete foreign or toxic 
compounds by enzyme-dependent metabolism. 
In chemical carcinogenesis, the transformation of chemicals is 
important in both bioactivation and detoxification. Metabolic activation of 
procarcinogens by xenobiotic metabolizing enzymes (XMEs) is often 
needed to initiate the process (Pelkonen 0” 1992; Raunio H. et al., 1995). 
Competing with enzymatic activation are detoxification pathways that may 
convert potential genotoxins to less carcinogenic, more readily excreted 
polar metabolites. XMEs are categorized into two groups, phase I 
(fictionalization reactions) and phase I I enzymes (conjugation reactions) 
(Nebert D.W. et al., 1987; Nebert D.W. et al., 1996; Nelson D.R. et al., 
1996). Phase I reactions generally convert foreign compounds to derivatives 
that can undergo phase I I reactions. 
Phase I enzymes mediate the first step in the metabolism of 
carcinogens into more hydrophilic forms. These enzyme families are 
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categorized by their ability to metabolize different substrates (Guengerich 
F.R，1992a; Guengerich F.R, 1992b). The most important enzyme systems 
involved in phase I reactions are the cytochrome P-450-related enzymes 
(Wickramasinghe R.H., 1979). These enzymes add small molecules (e.g., 
OH- or 0-groups) to their substrates. Multiple forms of cytochrome P-450 
enzymes exist in the liver of various mammalian species (Lu A.Y. et al., 
1979). In rat, there are 60 sequenced CYP genes and 4 pseudogenes, most 
of which could be divided into four main families: CYPl , CYP2, CYP3 and 
CYP4 (Nelson D., 1998). 
Phase I I enzymes usually detoxify, but sometimes also activate, 
endogenous or exogenous compounds (Hayes J.D. et al, 1995). 
Conjugation reactions involve the addition to foreign compound of 
endogenous substances that are generally polar and readily available in vivo 
(Caldwell J” 1982). These substances are converted into a more hydrophilic 
form by conjugating with a suitable functional group. Very lipophilic 
compounds are usually first metabolized by phase I enzymes and then by 
phase I I enzymes, whereas less lipophilic compounds can be metabolized 
directly by phase I I enzymes. An important phase I I reaction is glutathione 
conjugation. The reaction is catalyzed by the glutathione S-transferases 
(GSTs), which are a family of enzymes that catalyze the conjugation of 
glutathione and foreign compounds. 
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Chapter 2 Materials and methods 
2.1 Preparation of aqueous extract of Agrimonia pilosa 
Agrimonia pilosa (AP) was purchased from a local store. The root 
slice was first cut into smaller pieces by scissors. The pieces were soaked in 
an appropriate volume of nano-pure water (1 g root /lO mL) for 16 h and 
boiled for 2 h under reflux. The aqueous solution was removed and the 
residues were boiled for another 2 h in fresh water. 
The aqueous extract was collected and divided into two parts for in 
vivo and in vitro study. For in vivo study, the extract was reduced to a final 
concentration equaling 1 g raw AP in 1 mL water by heating. It was stored 
at 4。C before use. For in vitro study, the aqueous extract was cooled to 
room temperature and centrifuged at 11,000 g for 10 min to remove large 
particles. The supernatant was recentrifuged to ensure that no trace amounts 
of smaller particulates were present. The extract was then filtered through a 
Millipore Durapore® 0.45 inm HV membrane and a Millipore 0.22 |im 
GSWP membrane for sterilization. Finally, the clear extract was quickly 
frozen in liquid nitrogen and lyophilized using a freeze-dryer. The collected 
powders could be dissolved in different concentrations when exerted on 
cells. Before that, the extract should be refiltered through 0.22 \im GSWP 
membrane for sterilization. 
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2.2 In vivo study 
2.2.1 Animal model for hepatocarcinogenesis 
2.2.1.1 Chemical carcinogens 
Chemical carcinogens are widely employed to develop cancers in 
specific organs of experimental animals, as it is able to induce hepatoma 
within a short time and can be administered by a variety of methods (Ha 
WS.etaL, 2001). 
Among these carcinogens, diethylnitrosamine (DEN) has been 
frequently used to study hepatocarcinogenic process. It has recently been 
reported that hepatoma can be induced by the administration of DEN in 
combination with CCU (Kovalszky, I. et cd., 1992) 
Diethylnitrosamine (DEN), also known as N-Nitrosodiethylamine 
(NDEA) is a genotoxic carcinogen that exclusively resulted in liver cancer. 
Its chemical structure is shown in Figure 2.1. 
DEN is carcinogenic in all animal species tested and thus concluded by 
the International Agency for Research on Cancer review (lARC，1978) as a 
probable human carcinogen (Group 2A). 
One major putative mechanism for DEN induced carcinogenesis is 
DEN-DNA adduct formation. The first bioactivation step is P450-mediated 
a-hydroxylation, producing an a-hydroxylnitrosamine, 
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N-Nitroso-N-ethyl-N-(2-hydroxyethyl)-amine, which was reported to 
produce mainly liver tumors after its oral administration to rats (lARC, 
1978). DEN is hydroxylated principally by CYP2E1 in liver, but other P450 
isozymes were found to be involved as well (Swenberg J.A., et al., 1991). 
DNA-adduct formation proceeds through an ethyl diazonium ion 
intermediate and evolution of N2 (Michejda C.J. et al., 1982; Singer B. et 
al； 1983). 
Carbon tetrachloride (CCI4) is a nongenotoxic carcinogen (Figure 2.1). 
It can produce liver neoplasms in mice and rats and mammary neoplasms in 
rats following subcutaneous injection, and is concluded by the International 
Agency for Research on Cancer review (lARC, 1999) as a possible human 
carcinogen (Group 2B). 
It was reported that CCI4 could induce hepatic cell proliferation and 
DNA synthesis. In experiments involving administration of CCI4 and other 
carcinogens, the occurrence of tumors and/or preneoplastic lesions of the 
liver in mice，rats and hamsters were enhanced. A l l these suggested CCI4 be 
a good promoter in the process of hepatocarcinogenesis. (lARC, 1999) 
CCI4 is thought to be metabolized by the hepatic cytochrome P-450 
enzymes (especially CYP2E1) with the production of the highly toxic 
trichloromethyl radical, which binds to macromolecules, initiating lipid 
14 
A 
C H , — C H , \ 
— N SSzzzrtiQ 
/ 




C I — C — C I 
C I 
Figure 2.1 (A) Chemical structure of diethylnitrosamine (DEN). 
(B) Chemical structure of carbon tetrachloride (CCI4). 
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peroxidation and destroying cell membranes (Bini A. et al., 1975). The 
resulting metabolites depend on the aerobic state of the tissue in which 
metabolism occurs (ATSDR, 1989) and include chloroform, 
hexachloroethane, and possibly phosgene (Fowler J.S., 1969; Shah H. et al., 
1979). The trichloromethyl radical can also combine with oxygen to form 
peroxy free radicals capable of binding to cellular molecules (Rao K.S. et 
al； 1969). 
2.2.1.2 Animals 
Male Fischer 344 rats were used as in vivo model in this project. The 
Fischer 344 rat is commonly used for cancer research, toxicology and aging 
studies. It has a longer life span, smaller body size and lower spontaneous 
tumor rate than non-inbred rats. The Fischer 344 is the inbred rat model of 
choice for the National Toxicology Program's Carcinogen Bioassay 
Program. 
In present study, rats about 6-7 week old, with the body weight of 
90-100 g，were supplied by the Laboratory Animal Services Centre, the 
Chinese University of Hong Kong. The rats were housed in plastic cages in 
a controlled environment of 18-20。C, humidity 54-56% with a 12-h 
light-dark cycle. They were supplied with standard animal chow (Supastok 
Autoclavable Rodent Diet, Ridley Agriproducts, Australia) and allowed free 
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access to tap water throughout the experimental period. After a one-week 
acclimation period, the rats were randomly divided into eight groups, each 
group with 5-6 animals. 
2.2.1.3 Animal treatment and sacrifice 
Chemicals and reagents 
Toxins and vehicles: Diethylnitrosamine (DEN) (0.95 g/mL, from Sigma) 
was diluted by DMSO (Sigma) to the final concentration of 190 mg/mL. 
Carbon tetrachloride (CCI4) (Merck), DMSO (Sigma) and com oil (from 
local Market) were prepared. 
Perfusion buffer: Tris-sucrose buffer containing 50 m M Tris (USB) and 
0.25 M sucrose (Sigma) was prepared in nano-pure water. The final pH was 
adjusted to 7.4. The solution was stored at 4°C before use. 
Fixing reagent: Ethanol (70%) and phosphate buffer (100 mM, pH 7.4) 
containing 4% paraformaldehyde (Sigma) and 20 mg/L heparin (USB) was 
prepared. 
The experimental animals were divided into three sets, namely: the 
AP-alone treatment groups, including vehicle-control group (Group 1) and 
AP-alone treatment group (Group 2); the co-treatment groups, including 
vehicle-control group (Group 3), toxin-control group (Group 4) and AP 
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co-treatment group (Group 5); the post-treatment groups, including 
vehicle-control group (Group 6), toxin-control group (Group 7) and AP 
post-treatment group (Group 8). The protocol for animal treatment is shown 
in Figure 2.2. 
Briefly, rats in Group 1 and Group 2 were used to study the AP 
effects on the rat liver without toxin treatment. The rats received 1 ml/kg 
body weight of AP by oral injection daily (Group 2) or water as vehicle 
(Group 1) for 5 weeks. The other groups were used to study protective 
effects of AP on DEN-CCI4 induced hepatocarcinogenesis in 
initiation-promotion stage or post-promotion stage. The rats were 
administered an intraperitoneal dose of 100 mg/kg body weight DEN 
(Groups 4, 5，7 and 8) or DMSO as the vehicle (Groups 3 and 6). The next 
week 1 ml/kg body weight CCI4 (Groups 4, 5, 7 and 8) or com oil as the 
vehicle (Groups 3 and 6), was administrated by i.p. injections once a week 
for 4 weeks. For AP treatment, the rats received 1 ml/kg body weight of AP 
by oral injection daily (Groups 4，5，7 and 8) while water was administrated 
instead in control groups (Groups 3 and 6). In co-treatment groups (Groups 
3, 4 and 5), such treatment was performed from the very beginning of 
experimental period and last for 5 weeks until sacrifice date. Whereas in 
post-treatment groups (Groups 6, 7 and 8)，the AP treatment was carried out 
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Figure 2.2 Protocol for animal treatment 
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sacrifice of animal. A l l animals were weighed once a week during the entire 
experimental period. About 24 hours after the last administration of AP or 
water, animals were weighed and sacrificed. 
A l l rats were sacrificed by exsanguination under N2 euthanasia. Livers 
were excised after perfusion and weighed. Three slices of 5-iiim-thickness 
were taken from each liver, fixed in 4% paraformaldehyde for 24 hr, and 
then 70% ethanol for 48 hr. The remaining liver portions were immediately 
frozen in liquid nitrogen and then stored at -80。。until biochemical tests. 
2.2.2 Histological and immunohistochemical study 
Chemicals and reagents 
Reagents for dehydration and deparaffinization: Two series of Xylene 
(X3), 100% ethanol (X2), 95% ethanol, 80% ethanol and 70% ethanol were 
prepared. Xylene was purchased from Mallinckrodt. Ethanol was purchased 
from BDH. 
Reagents for Hematoxylin and Eosin (H & E) staining: A set of acid 
alcohol. Hematoxylin and Eosin working solution were prepared. 
1% H2O2： It was freshly prepared by diluting 10 mL 30% H2O2 (Sigma) in 
300 mL nano-pure water. 
2 0 
Citric acid buffer: One liter of 0.21% (w/v) citric acid (USB) was prepared 
wi th nano-pure water. The final pH was adjusted to 6.0. 
Phosphate buffered saline (PBS): Phosphate buffered saline was prepared 
by dissolving 8.18 g sodium chloride, 0.2 g potassium chloride，0.2 g 
potassium dihydrogen phosphate and 1.44 g sodium hydrogen phosphate in 
1 L of nano-pure water. The final pH was adjusted to 7.4. A l l chemicals 
were purchased from Sigma Chemicals. 
Antibodies: The primary antibody was kindly donated by Second 
Department of Biochemistry, School of Medicine, Hirosaki University. The 
secondary antibody Anti-Rabbit IgG and Goat Normal Serum were obtained 
from VECTASTAIN ABC KIT. Antibodies were diluted by 300 times 
before use. 
3,3'-diaminobenzidme (DAB) solution: DAB (Sigma) solution was 
prepared by dissolving 15 mg of DAB in 300 mL of PBS containing 40 ^iL 
of30%H202. 
The fixed tissues were dehydrated in a series of ethanol and xylene, 
embedded in paraffin and cut into sections of 5 ^im in thickness. A t least 
two slides with three serial sections on each were prepared from each liver 
specimen. One slide was employed for histological examination after 
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hematoxylin and eosin staining, and the other was utilized for the 
immunohistochemistry study of GST-P foci. 
For histological study, the fixed sections were deparaffinized in xylene 
and rehydrated by passage through an alcohol series and then stained by 
hematoxylin and eosin (H & fi staining) in a routine procedure, finally 
mounted on slides and observed under light microscope. 
For immunohistochemical study, the fixed sections were deparaffinized 
in xylene and rehydrated by passage through an alcohol series. Endogenous 
peroxidase was quenched in 1% H2O2 (aq) for 5 min at room temperature. 
After washing under tap water for 5 min, the slides were heated in the Citric 
Acid buffer (pH 6.0) in microwave for 5 min. 
After washing under tap water, a standard avidin/biotin (ABC) 
protocol was followed. The sections were incubated in Normal Serum for 
30 min, and excess normal serum was drained. Primary antibody was 
applied overnight at 4°C in the moist chamber. 
Sections were washed in PBS for three changes per 5 min. GST-P 
secondary antibody was applied to sections at room temperature for 30 min. 
After washing with PBS for three changes, ABC was applied to sections for 
30 min at room temperature. After washing again，sections were incubated 
2 2 
in DAB solutions and checked frequently under microscope to avoid 
over-staining. Sections were exposed to final washing prior to dehydration 
and mounting. 
Pictures of the liver sections (lOOX and 200X) were taken by 
Axiophot-2 Universal Microscope (Zeiss) coupled with Spot 32 image 
capture software (Diagnostic Instruments). GST-P foci were measured by 
the MetaMorph 4.0 image analysis system (Universal Imaging Corporation). 
A slide with three serial sections from each rat was analyzed. The area 
percentage of foci recorded was the average of three slides. 
2.2.3 Preparation of liver homogenates and microsomes from rat 
Chemicals and reagents 
Tris-sucrose buffer: Tris-sucrose buffer containing 50 m M Tris (USB) and 
0.25 M sucrose (Sigma) was prepared in nano-pure water. The final pH was 
adjusted to 7.4. The solution was stored at 4。C before use. 
Phosphate buffer: Phosphate buffer containing O.IM potassium phosphate 
(Sigma), 20% glycerol (USB) and 1 m M EDTA was prepared. pH was 
adjusted to 7.25. 
Homogenization of the livers was performed in Tris-sucrose buffer. 
After centrifugation at 10,000 g for 20 min, the supernatant was collected 
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and divided into 2 parts. One part was saved for GST and COX-2 enzyme 
assays. The other was further centrifuged for 75 min at 105,000 g. The 
microsomal pellets were washed once with Tris-sucrose buffer, 
recentrifaged at 105,000 g for 75 min, and finally suspended in potassium 
phosphate buffer. The liver homogenates and microsomes were stored at 
-80。C until use. 
2.2.4 Determination of protein concentration 
Bradford protein dye: Bio-Rad Protein Assay Dye Reagent Concentrate 
was ready for use. 
Protein concentration was determined according to the method of 
Bradford (Bradford M . M ” 1976) with bovine albumin as the standard. A 
standard curve was established using different dilutions of 15 |ig/mL bovine 
serum albumin. An aliquot of 800 ^iL of samples or standard protein was 
added to 200 |iL of dye reagent concentrate. They were mixed by vortexing 
and incubated for at least 5 min at room temperature. The absorbance at 595 
nm was measured by spectrophotometer. The concentration of samples was 
calculated from the standard curve with an appropriate dilution factor. 
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2.2.5 COX-2 Activity Assay 
Chemicals and reagents 
Phosphate buffer: Potassium phosphate buffer containing 100 m M 
potassium phosphate was prepared. The final pH was adjusted to 7.5. 
Tris phenol buffer: Tris phenol buffer containing 0.1 M Tris and 0.5 m M 
phenol was prepared. The final pH was adjusted to 7.3. 
Hematin: A stock of hematin (0.380 mg/mL) (Sigma) was prepared in 
DMSO. One microliter of 0.380 mg/mL hematin was diluted in 2.5 mL 
phosphate buffer to a final concentration of 0.24 ^iM before use (stable for 8 
h at room temperature). 
N,N,NSN'-tetramethylphenylenediamme (TMPD): A stock of TMPD 
(Sigma) was prepared as 50 m M in ethanol. Before use, it was diluted to 2.5 
m M with nano-pure water, and kept on ice and avoided exposure to light. 
Arachidonic acid: A stock of arachidonic acid (Sigma) was prepared (50 
mg/mL) in ethanol under nitrogen and stored in dark at -70 "C. Before use, 6 
^L of ethanolic arachidonic acid was diluted with 9 4 ^ L o f 0 . 1 N NaOH and 
then diluted with 9.9 mL of nano-pure water. It was kept on ice until use. 
Selective COX-1 inhibitor: SC-560 solution purchased from Cayman 
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Chemical was ready for use. 
The reaction was carried out following the protocol from IBL 
IMMUNO-BIOLOGICAL Laboratories with modifications. About 50 pL of 
Tris-phenol buffer, 25 ^iL of 0.24 \ M hematin, and 50 ^L of sample protein 
was added to each designated well on the 96-well plate. Inactive samples 
were also added to background wells. The plate was shaken for a few 
seconds to mix and incubated at room temperature for 5 min. An aliquot of 
25 loL SC-560 was added to each sample well and incubated for about 30 
min. After adding 50 \iL of TMPD to each well, the reaction was initiated 
by adding 50 \iL of dilute cold arachidonic acid. The plate was shaken for a 
few seconds and incubated for 5 min at room temperature. The absorbance 
at 590 nm was read using a plate reader. The activity of each sample was 
calculated by the formula provided by IBL protocol with modification. A l l 
experiments were performed in triplicate. Data were analyzed by the 
Student's t test (n = 5-6). 
2.2.6 Cytochrome P450 2E1 Assay 
Chemicals and reagents 
Phosphate buffer: Phosphate buffer containing 50 mM potassium 
phosphate (Sigma) was prepared. pH was adjusted to pH 7.4. 
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Protein working solution: The isolated microsomes from rat liver were 
diluted with assay buffer to a final concentration of 5 mg/mL. 
/7-nitrophenol: ；7-Nitrophenol (5 mM) (Sigma) was prepared in assay buffer. 
The solution was stored in dark before use. 
Deproteinizing agent: 20% (w/v) trichloroacetic acid (TCA， from Sigma) 
was prepared. 
Sodium hydroxide (NaOH): NaOH (Sigma) was prepared as 2 M in 
nano-pure water. 
p-Nitrophenol hydroxylation assay was performed as described by 
Zhao (Zhao Z.S. et al., 1996) with modifications: the reaction mixture 
contained 50 m M potassium phosphate buffer, pH 7.4，100 |xM 
；7-Nitrophenol, 1 m M NADPH. After pre-incubation at 37。C for 5 min, the 
reaction was initiated by adding 40 |aL of microsomes working solution 
(200 |ig protein). The assay mixture was incubated at 37°C in the dark for 0， 
5，10 and 20 min, respectively, and terminated by adding 100 j iL of 20% 
(w/v) trichloroacetic acid. The assay mixture was centrifuged at 10,000 g 
for 5 min. About 0.5 ml of the supernatant was transferred to a curvet 
containing 0.25 mL of 2 M NaOH and the absorbance was monitored at 546 
nm. The amount of ；?-nitrocatechol produced was determined using the 
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molar extinction coefficient of 9.53 m M ] cm"\ A l l experiments were 
performed in triplicate. Data were analyzed by the Student's t test (n = 5-6). 
2.2.7 Spectrophotometric Assay for GST 
Chemicals and reagent 
Phosphate buffer: 0.2 M sodium phosphate (USB) was prepared. The final 
pH was adjusted to 6.6. 
Protein working solution: The prepared liver homogenates were diluted 
with assay buffer to the final concentration of 1 mg protein/ml. 
Glutathion (GSH): Glutathion (reduced form, from Sigma) was prepared 
as 20 m M in nano-pure water. 
l-Chloro-2, 4-dinitrobenzene (CDNB): l-Chloro-2, 4-dinitrobenzene 
(Sigma) was prepared as 20 mM in 95% Ethanol. 
This assay was modified from a continuous spectrophotometrically 
monitored method (Mannervik B. et al., 1981). About 850 \iL Sodium 
Phosphate Buffer was preincubated at 31°0. GSH (50 ^iL), CDNB (50 ^iL) 
and enzyme working solution (50 |iL) were added to each tube one after 
another. The sample tubes were mixed gently and completely and the 
absorbance was read at 340 nm continuously for at 2 min at STC. For 
Control 1, an aliquot of 50 ^iL buffer instead of enzyme working solution 
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was added, while for Control 2, an aliquot of 50 \iL buffer instead o fCDNB 
was added. The enzyme activity was expressed as the number of jimole 
product formed per mg protein per min at STC. The amount of final 
product was determined using the molar extinction coefficient of 9.6 nM"^ 
cm\ A l l experiments were performed in triplicate. Data were analyzed by 
the Student's t test (n 二 5-6). 
2.2.8 Isolation of total RNAfrom liver homogenate 
Chemicals and reagents 
Diethyl pyrocarbonate-treated water: It was prepared by adding diethyl 
pyrocarbonate (DEPC, from USB) to autoclaved nano-pure water to the 
final concentration of 0.1% by volume. The water was stirred overnight and 
autoclaved before use. 
Organic solvents: Chloroform and isopropanol were purchased from BDH 
whereas 12.3 M formaldehyde was obtained from Sigma. Trizol reagent 
(Gibco BRL) was ready for use. 
IX TE buffer: The buffer contained 10 m M Tris-HCl pH 8.0 and 1 mM 
ethylenediaminetetraacetic acid (EDTA). A l l chemicals were obtained from 
USB. 
lOXMOPS buffer: This buffer was prepared in DEPC-treated water 
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containing 0.4 M MOPS (USB) pH 7.0，0.1 M sodium acetate (Sigma) and 
10 m M EDTA. It was filter-sterilized and stored in the dark. 
RNA sample buffer: The buffer contained 10 mL of deionized formamide 
(USB), 3.5 mL of 12.3 M formaldehyde, 1 ml of lOX MOPS buffer and 1 
mL ofDEPC-treated water. I t was stored at -201； before use. 
R N A loading buffer: The buffer contained EDTA (1 mM, pH 8.0), glycerol 
(50o/o v/v, USB), bromophenol blue (0.25% w/v, from Sigma) and xylene 
cyanol (0.25% w/v, from Sigma). It was filtered and stored at -20。C before 
use. 
LOX TBE: The buffer contained 0.9 M Tris base, 0.9 M boric acid and 20 
m M EDTA, pH 8.0. A l l the chemicals were purchased from USB. 
0.5X TBE: The working buffer (0.5X TBE) was diluted from lOX TBE 
with nano-pure water. 
6X DNA loading dye: Sucrose (40% w/v, from Sigma), bromophenol blue 
(0.025% w/v) and xylene cyanol (0.025% w/v) were mixed and stored at 
-20。C 
Formadehyde agarose gel (for RNA): The gel mixture containing 1.5% 
(w/v) agarose powder (BioRad), I X MOPS and DEPC-treated water was 
boiled to dissolve the agarose and cooled down at room temperature. 
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Formaldehyde was added to adjust a final concentration to 2.2 M. The gel 
solution was mixed thoroughly before pouring into gel casting mould for 
solidification. The gel was stained with DEPC-treated water containing 5 
Iig/mL ethidium bromide (EB, from USB) after electrophoresis. 
An amount of 50-100 mg of liver tissue was derived from frozen 
sample and homogenized in 1 mL of Trizol reagent. The homogenized 
sample was incubated at room temperature for 5 min to permit complete 
dissociation of nucleoprotein complexes and then centrifuged at 12,000 g 
for 10 min to remove the unhomogenized tissue. The supernatant was 
removed to a new microtube and 0.2 mL of chloroform was added. The 
sample was mixed vigorously prior to incubation at room temperature for 
15 min. Then it was centrifuged at 12,000 g for 10 min at 4°C. The top 
aqueous phase which contained the RNA was carefully removed and 
transferred to a fresh microtube. RNA was precipitated by mixing the 
aqueous phase with 0.5 mL isopropanol prior to incubation at room 
temperature for 15 min to allow complete precipitation of RNA. RNA pellet 
was collected after centrifugation at 12,000 g for 15 min at 4°C followed by 
washing once with 1 mL of 75% ethanol and centrifugation at 7,500 g for 5 
min at 4°C. After ethanol was completely removed, RNA pellets were 
allowed to dry at room temperature. The total RNA was finally dissolved in 
50-100 |iL of autoclaved DEPC-treated water, incubated at 55 to 60°C for 
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10 min with vortex discontinuously. The samples were kept at -20°C for 
temporary storage or at -70°C for long-term storage. The quality and 
integrity of total RNA were checked by UV spectrophotometry and 
formaldehyde agarose gel electrophoresis. 
2.2.9 Semi-quantitative RT-PCR analysis 
Chemicals and reagents 
Reverse transcription reaction mixture: The reaction mixture contained 5 
路 of total RNA, 500 ng ofol igo dT primer (Roche), 500 | iM of each dNTP 
(Sangon), 4 pL 5X First Strand Buffer, 2 ^ L 0 . 1 M dithiothreitol (DTT), and 
200 unit of Superscript I I (Gibco BRL) in a total volume of 20 pL. 
PCR reaction mixture: Each PGR reaction contained 0.5 j iL of cDNA 
(synthesized from reverse transcription), 20 m M Tris-HCl, pH 8.4, 50 m M 
KCl, 1 m M dNTP mixture, 1.5 m M MgCla and 0.25 jxM primer mixture and 
2.5 U of recombinant Taq polymerase (Sangon) or Hot Star Taq polymerase 
(QIAGEN). 
Agarose gel (for DNA): The gel mixture containing 1.5% (w/v) agarose 
powder (BioRad) and 0.5X TBE was boiled to dissolve the agarose and 
cooled down at room temperature. The gel solution was mixed thoroughly 
before pouring into a gel casting mould for gel formation. The gel was 
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stained with 5 ^ig/mL ethidium bromide (EB， f rom USB) after 
electrophoresis. 
Reverse Transcription of mRNA to cDNA by Superscript I I was 
performed. A 20-|il reaction volume was used for 5 jiig of total RNA 
reaction. In reverse transcription reaction, the mixture of total RNA and 
oligo-dT primer was incubated at 70。C for 10 min and then quick chilled on 
ice. The contents of the tube were collected by brief centrifugation and 5X 
First Strand Buffer, 0.1 M DTT，10 m M dNTP Mix were added. The 
contents were incubated at 42°C for 2 min before adding 200 units of 
SUPERSCRIPT II. Reverse Transcription was then performed at 42°C for 
50 min in a Perkin-Elmer GeneAmp® PGR system 9700. Samples were 
denatured for 15 min at 70。C and chilled on ice. 
The protocol for semi-quantitative RT-PCR was similar to that of the 
conventional RT-PCR analysis with well controlled conditions. Taq 
polymerase or Hot Star Taq polymerase was employed. The latter was used 
to perform automatic hot start PGR reaction in order to analyze particular 
genes. A l l PGR reactions were carried out in the linear, quantitative phase 
of the amplification process, which was determined in preliminary 
experiments. Each cycle consisted of three different temperatures for 
denaturation, annealing and extension. The PGR mixture was incubated for 
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several minutes prior to amplification and a final extension step at 72°C for 
10 min was performed after all cycles were completed. For Taq polymerase, 
the incubation was performed at 94 °C for 3 min, while for Hot Star Taq the 
condition was at 95 °C for 15 min. 
After the PGR reaction, the size and the quantity of the PGR products 
were analyzed by gel electrophoresis. The band intensity of a particular 
gene (Gi) was measured by Molecular Dynamic Densitometer. The band 
intensity of p-actin gene (BO was measured as an internal control. The ratio 
of the band intensities (Gi； BO was used to compare the mRNA level of each 
gene after treatment. 
The primer sequences applied in current study and their application 
































































































































































































































































































































































































2.3 In vitro study 
2.3-1 Cell cultures 
Cell lines and reagents 
Cell lines: The cell line H4IIE is a hepatoma cell line derived from Sprague 
Dawley rat, while Clone 9 is a normal liver cell line derived from Sprague 
Dawley rat. Both of the cell lines were purchased from American Type 
Culture Collection. 
H4IIE medium: Modified Eagle Medium (MEM) with Earle's Balanced 
Salt Solution and non-essential amino acids, antibiotic mixture including 
penicillin, streptomycin and neomycin (PSN), fetal bovine serum (FBS) and 
calf serum (CS) were purchased from Gibco BRL (5.958 HEPES g/L) and 
sodium bicarbonate (3.7 g/L) was obtained from Sigma Chemicals. These 
solutions were added to M E M before adjusting the pH to 7.2. Complete 
m e m was prepared by adding PSN, FBS and CS to the final concentration 
of 1%, 10% and 10% (v/v) respectively to MEM. The medium was filtered 
through 0.22 ^m Millipore Steritop™ GT membrane for sterilization and 
stored at 4°C until use. 
Clone 9 medium: Dulbecco's modified Eagle medium (DMEM) with 4.5 
g/L glucose and 4 m M L-glutamine was obtained from Gibco BRL. HEPES 
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(5.958 g/L) and sodium bicarbonate (3.7 g/L) were added to D M E M and 
the final pH was adjusted to 7.2. 1% PSN and 10% FBS were included in 
complete DMEM. The medium was filtered through 0.22 _ Mill ipore 
Steritop™ GT membrane for sterilization and stored at 4°C until use. 
phosphate buffered saline (PBS): Phosphate buffered saline was prepared 
by dissolving 8.18 g sodium chloride, 0.2 g potassium chloride, 0.2 g 
potassium dihydrogen phosphate and 1.44 g sodium hydrogen phosphate in 
1 L of nano-pure water. The final pH was adjusted to 7.4. It was autoclaved 
(12 rC , 15 psi, 20 min) for sterilization. A l l chemical used were purchased 
from Sigma Chemicals. 
Trypsin-EDTA: T r y p s i n - E D T A purchased from GIBCOBRL was ready for 
use. 
Trypan blue: It was prepared as 0.4% (w/v) in PBS, for cell counting 
staining 
Cells were kept in culture medium at 37。C in a 5% CO2 incubator. 
They were subcultured when 80% confluence was reached. If necessary, the 
viability and the quantity of the cells were determined by the trypan blue 
exclusion assay. 
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2.3.2 Cytotoxicity assay 一 Neutral Red Assay 
Chemicals and reagents 
Neutral red solution: Neutral red solution (0.5%) was prepared by 
dissolving neutral red powders (Sigma) in 0.9% saline. The solution was 
then filtered through Whatman 3 M M paper and stored at 4°C in the dark. 
phosphate buffered saline (PBS): PBS ( IX ) was prepared as described 
before. 
Sodium dodecyl sulfate solution (SDS): For cell lysis, 1% SDS solution 
was used. 
A fixed number of cells (1000/well) in complete medium were seeded 
in the wells of a 96-well plate. After 48 h incubation, different 
concentrations of drugs were added to each well. The plate was incubated 
for another 5 days before Neutral Red assay was performed. The culture 
medium of each well was removed. The cells were washed with 100 pL of 
PBS twice prior to incubation with 50 i iL of neutral red solution at 3TC for 
an hour. When the incubation was completed, neutral red solution was 
removed and the cells were washed twice with PBS. The plate was allowed 
to dry overnight. About 100 ^L of 1% sodium dodecylsulfate (SDS) were 
added to redissolve the neutral red in the cells. Absorbance at 540 nm of 
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each well was recorded by a Plate Reader using 1% SDS as the blank. 
2.3.3 Cell cycle distribution analysis by flow cytometry 
Chemicals and reagents 
phosphate buffered saline (PBS): PBS (IX) was prepared as described 
before. 
Staining solution: PBS solution containing 5 ^ig/ml propidium iodide (PI, 
from Sigma) and 100 ^ig/mL Rnase A (USB) was prepared. 
Shealth fluid: Shealth fluid was purchased from FACSFlow™ and ready 
for use. 
PI staining was used to analyze D N A content. Cells were plated in 
3-cm culture dishes at concentrations determined to yield 60-70% 
confluence within 2, 4，8, 24, 48 and 72 h，respectively. After that, cells 
were treated with AP extract of different concentrations. After a certain 
period of incubation，both adherent and floating cells were harvested, and 
the cells were labeled with PL Briefly, cells were resuspended in PBS, fixed 
with 70% ethanol, labeled with PI staining solution, incubated at 37°C in the 
dark for 30 min. DNA content was analyzed using a FACScan instrument. 
39 
2.3.4 DNA fragmentation 
Chemicals and reagents 
Lysis buffer: Lysis buffer containing 200 m M Tris-HCl, 100 m M EDTA 
and 1% SDS was prepared. The final pH was adjusted to pH 8.3. 
Proteinase K solution: Proteinase K (Gibco BRL) was prepared as a 
10-mg/mL solution. 
Saturated sodium chloride (NaCl) solution: Excessive NaCl (USB) was 
dissolved in nano-pure water to make a saturated solution at room 
temperature. 
Solvents: Cold absolute ethanol and -20 70% ethanol were prepared. 
TE buffer: I X TE containing 0.2 mg/mL ofRNase A (USB) was prepared. 
0.5X TBE: The working buffer (0.5X TBE) was diluted from lOX TBE 
with nano-pure water. 
6X DNA loading dye: Sucrose (40% w/v, from Sigma), bromophenol blue 
(0.025% w/v) and xylene cyanol (0.025% w/v) were mixed and stored at 
-20。C 
Agarose gel (for DNA): The gel mixture containing 1.5% (w/v) agarose 
40 
powder (BioRad) and 0.5X TBE was boiled to dissolve the agarose and 
cooled down at room temperature. The gel solution was mixed thoroughly 
before pouring into a gel casting mould for gel formation. The gel was 
stained with 5 ^ig/mL ethidium bromide (EB, from USB) after 
electrophoresis. 
Cells were seeded in 10 cm' cell culture plates and incubated with 
desired concentrations of herbal extracts in a humidified incubator (37。C in 
讽 C02) for the desired time. Then cells were harvested and washed once 
with PBS. The washed-cells were fully suspended in 400 ^iL of lysis buffer 
in 1.5 mL eppendorf tubes. About 20 ^iL of prepared proteinase K was 
added to digest the proteins, and then the tubes were incubated in 3TC 
water bath for at least 2 h. Then, the samples were cooled down to room 
temperature and 150 ^iL of saturated NaCl solution was added. After 
centrifuging for 15 min at 10,000 g, supematants were collected. DNA 
fibers were obtained by adding 1 ml cold absolute ethanol and centrifuged 
for 20 min in 4 at 14,000 g. Then the DNA fibers were washed once 
with 500 ^iL of -20°C 70% EtOH and then the DNA pellet was dried in 
70。C oven. After the dried DNA pellet was obtained, 25 ^iL of TE buffer 
(10 m M Tris-HCl pH 8.0，1 m M EDTA) containing 0.2 mg/ml of RNase A 
was added，and incubated at 37。C for 90 min. 10 ^iL of each DNA sample 
was loaded on 1.5% agarose gel in 0.5% TBE buffer to investigate i f any 
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DNA ladders could be formed or not. 
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Chapter 3 Results 
3.1 In vivo study 
3.1.1 Body weight and relative liver weight 
The changes of average body weight and relative liver weight in rats of 
each group at the end of 5 weeks and 10 weeks are shown in Table 3.1. 
At the end of 5 weeks, in AP co-treatment groups, toxin (DEN & CCI4) 
treatment (Groups 4 and 5) caused a dramatic decrease in the body weight 
while no significant difference was observed between Group 4 
(toxin-control) and Group 5 (AP co-treatment). In addition, the relative liver 
weight was slightly decreased after toxin treatment (Groups 4 and 5), also 
without significant difference between the two groups. However, treatment 
with AP alone did not influence the relative liver weight but slightly 
decrease the body weight when compared with vehicle control. 
The rats in Group 5 were fed with AP in addition to toxin treatment. 
The body weight was slightly higher than the toxin-control group (Group 4) 
though lower than the vehicle-control group (Group 3). In addition, the 
relative liver weight was lower than both the vehicle-control group and the 
toxin-control group (Groups 3 and 4). Treatment with AP alone (Group 2) 
also decreased the body weight without affecting the relative liver weight 
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when comparing with its vehicle-control (Group 1). In the AP 
post-treatment groups, the body weight was lower after toxin (DEN & C C 。 
treatment (Groups 7 and 8). Post-treatment with AP (Group 8) showed no 
significant effects compared with the toxin-control group (Group 7). In 
contrast, there was no significant difference recorded in relative liver 
weight among the three groups (Groups 6, 7 and 8). 
A l l these results indicated that AP did not exhibit protective effects on 


















































































































































































































































































































































































































































































3.1.2 Gross Morphological changes 
Hardening and shrinkage of the liver with thickened border was 
observed in the toxin-treated rats from both the co-treatment and 
post-treatment groups (Groups 4, 5，7 and 8). The condition was more 
serious in the post-treatment groups, and nodules were found in the livers (3 
out of 5 rats). A l l of the vehicle-control groups (Groups 1, 3 and 5) and the 
AP-alone-treated group (Group 2) showed no abnormal appearance. 




Figure 3.1 (A) Rat liver from Group 1 (the vehicle-control group for AP-alone treatment). 
(B) Rat liver from Group 2 (AP-alone treatment group). There was no abnormal change 
in appearance in these two groups. 
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Figure 3.2 (A) Rat liver from Group 3 (the vehicle-control group for AP co-treatment). 
No abnormal appearance was observed. (B) Rat liver from Group 4 (the toxin-control 
group for AP co-treatment). Hardening and shrinkage of the liver with thickened border 
was noticed. (C) Rat liver from Group 5 (the AP co-treatment group). Hardening and 






Figure 3.3 (A) Rat liver from Group 6 (the vehicle-control group for AP 
post-treatment). The liver showed no abnormal appearance. (B) Rat liver from 
Group 7 (the toxin-control group for AP post-treatment). Serious hardening and 
shrinkage of the liver with thickened border was observed. One nodule was found in 
the liver. (C) Rat liver from Group 8 (the AP post-treatment group). Hardening and 
shrinkage of the liver with thickened border was also noticed but less serious than 
the toxin-control. No nodules were found in this group. 
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3.1.3 Hematoxylin and Eosin (H&E) staining for histological 
detection 
In the vehicle-control groups (Groups 1, 3 and 6), good distribution of 
hepatocyte cords around the central vein wi th the clear sinusoids was noted 
(Figures 3.4, 3.6 and 3.9). The healthy liver cells with clearly stained 
nucleus and cytoplasm were also observed. The AP-alone treatment group 
(Group 2) revealed no special difference compared with the vehicle-control 
groups (Figure 3.5). 
In the toxin-control groups (Groups 4 and 7), the normal architecture 
of the liver was lost. Strands of connective tissue divided the parenchyma 
into irregular pseudolobules as shown in Figures 3.7 and 3.10. The 
toxin-AP treated rats, either from co-treatment or post-treatment groups 
(Groups 5 and 8) showed less abnormal structure alteration when compared 
with the corresponding toxin control groups as shown in Figures 3.8 and 
3.11. In all the toxin-treated groups (Groups 4, 5, 7 and 8), the 
inflammatory reaction was indicated by the increased presence of 
immuno-cells, which are cells with important role in inflammation. 
In the toxin-control group of co-treatment (Group 4)，an altered hepatic 
focus was identified by the large pale cytoplasm and large nuclei in the cells 
of the foci. Thin fibrous septa with dissecting nodules could be seen though 
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it was still incomplete. In contrast to this, altered hepatocytes were also 
found but less severe in the rats from the AP co-treatment group (Group 5). 
In the toxin-control group of post-treatment (Group 7), cirrhosis was 
apparently indicated by the fibrous septa with dissecting nodules, which 
suggests a history of chronic liver damage. Regenerative nodules developed 
in the midst of scars are important for advancement of cirrhosis and 
neoplastic transformation. In the AP post-treatment group (Group 8), the 




Figure 3.4 Rat liver from Group 1 (the control-group for AP-alone treatment). 
Well distribution of hepatocyte cords around the central vein with the clear 
sinusoids was noted. H & E staining, XIOO. 
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Figure 3.5 Rat liver from Group 2 (AP-alone treatment group). The liver 
revealed no special difference to the vehicle-control groups. Well distribution 
of hepatocyte cords around the central vein with the clear sinusoids was 




Figure 3.7 Rat liver from Group 4 (the toxin-control group for AP 
co-treatment). The normal architecture of the liver was lost. An altered 
hepatic focus was identified by the large pale cytoplasm and large nuclei in 
the cells of the foci. Thin fibrous septa with dissecting nodules could be seen 
though it was still incomplete. The inflammatory reaction was indicated by 
the increase of immuno-cells. H & E staining, XI00. 
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Figure 3.10 Rat liver from Group 7 (the toxin-control group for AP 
post-treatment). The normal architecture of the liver was lost. Cirrhosis was 
apparently indicated by the fibrous septa with dissecting nodules, which in 
turn suggests a history of chronic liver damage. Regenerative nodules 
developed in the midst of scars. The inflammatory reaction was indicated by 
the increase of immuno-cells. H & E staining, XI00. 
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3.1.4 Effect of AP on DEN-CCU-induced GST-P positive foci 
formation and GST-P mRNA expression 
A. GST-P-positive-staining hepatic foci analysis 
Under microscopic examination, very few GST-P positive lesions were 
detected in specimens from the vehicle-control groups (Groups 1, 3 and 6) 
and the AP-alone treatment group (Group 2) (Figures 3.12, 3.13, 3.14 and 
3.17). In contrast, the administration of toxin (DEN-CCU) induced a 
substantial number of GST-P positive foci that were stained brown in both 
the toxin-control groups (Group 4 and 7) (Figures 3.15 and 3.18). The foci 
area was even larger in Group 7，which is believed to be due to the 
prolonged retaining period for foci development. Foci in rats administered 
with AP in addition to toxin (Groups 5 and 8) were generally fewer than in 
rats that were administrated toxin only, whether AP was administrated along 
with or after toxin treatment (Figures 3.16 and 3.19). 
Quantitative image analysis of GST-P positive lesions in rat liver 
specimens by software showed that there were distinct large portion of the 
sections occupied by altered foci in the toxin-control groups (Table 3.2). AP 
treatment markedly reduced the area of section occupied by GST-P positive 
foci, especially when AP was administered along with but not after the 
toxin treatment. This indicated a strong protection of AP against 
DEN-CCU-induced hepatocarcinogenesis. 
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B. RT-PCR analysis on GST-P mRNA expression 
The effects of AP on the initiation of DEN-CCU carcinogenesis were 
further assessed by the measurement of transcription of GST-P mRNA. 
Figure 3.20 shows the transcripts encoding GST-P mRNA from the 
representatives of each group. The expression of the amplified fragment 
corresponding to yS-actin mRNA is also shown for comparison. 
It was observed that the expression of GST-P mRNA was very low in 
the vehicle-control groups (Groups 1，3 and 6) and AP-alone treatment 
group (Group 2). DEN-CCU increased the expression of GST-P mRNA 
dramatically as reflected by the large amount of transcript visualized in 
toxin-control groups (Groups 4 and 7). On the other hand，AP produced a 
significant reduction in the level of GST-P transcript expression caused by 
DEN-CCU exposure in co-treatment group (Group 5). However, the 
reduction was not significant in the post-treatment group (Group 8). In 
order to eliminate variation arising from technical procedures, the level of 
the transcripts was normalized against that of the constitutively expressed 
house keeping yS-actin mRNA in the same sample and expressed as a ratio 

















































































































































































































































































































































































































































































^ 了〜》 r � \ ： � ‘ ^ - • � 
-r 0 U , 过 ， ， “ ‘ • 
/ , i - 、 孔 
？ -•/、•^ ,和，’‘ ‘ 、 » . , 
/ ^ / - ‘‘ ‘ “ • - • 
,一；0' K- ： 、 � • 
. 广 ‘ ‘ 
化 、 、 - -
义！乂 、 ‘ ^ < ‘ . ‘ ：、 f .， 、、 ^ -— -：…. 
1 八， ‘ ‘ • . . ；. 0 .  r • . 
/ 广’ V V , …丫、.�.广：• ‘ -
V , 、'.:. ^ .、:..…‘‘ 
. ’ . 金 “ 乂 ’ vt^ -.-.. , .prfV：,；? V . W • ： * 1 ‘ ^ ^  • 
^ ‘ ： .. .V , . . . 
• . , 4 .,. .‘...1 : ‘ : . : . . , . , 、 • . • ： • • -
v'-' : 、' ： $ 
• o , * ' ‘ 入 
Figure 3.12 Liver specimen from Group 1 (the vehicle-control 
group for AP-alone treatment). No GST-P positive foci were 
detected. Hematoxylin coimterstaining，X200. 
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Figure 3.13 Liver specimen from Group 2 (the AP-alone treatment 
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Figure 3.14 Liver specimen from Group 3 (the vehicle-control 
group for AP co-treatment). Few GST-P positive foci were detected. 
Hematoxylin coimterstaming，X200. 
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Figure 3.15 Liver specimen from Group 4 (the toxin-control group 
for AP co-treatment). A few GST-P positive foci were noted. The 
selected section demonstrated some single-cell positive foci. 
Hematoxylin counterstaining, X200. 
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Figure 3.16 Liver specimen from Group 5 (the AP co-treatment 
group). Few GST-P positive foci were noted, but much less than 
observed in Group 4. Hematoxylin counterstaining, X200. 
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Figure 3.17 Liver specimen from Group 6 (the vehicle-control 
group for AP post-treatment). Few GST-P positive foci were noted. 
Hematoxylin counterstaining, X200. 
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Figure 3.18 Liver specimen from Group 7 (the toxin-control group 
for AP post-treatment). Markedly increased GST-P positive foci 
were noted in the rats from this group. Enlarged GST-P positive 
foci with a mass of cells was demonstrated in the section. 
Hematoxylin counterstaining, X200. 
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Figure 3.19 Liver specimen from Group 8 (the AP post-treatment 
group). A few of GST-P positive foci were noted，but the condition 
was much less serious than found in Group 7. Hematoxylin 
counterstaining, X200. 
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Figure 3.20 (A) GST-P expression detected by RT-PCR. One representative 
sample from each experimental group was demonstrated. (B) GST-P 
expression level as demonstrated by GST-P: /?-actin ratio. The ratio of vehicle 
control was set as 1. All data were expressed as mean 士 SD (« = 5-6). Values 
statistically different from that of vehicle-control group (Groups 1，3, or 6) in 
Students /-test are indicated by M P < 0.05). Values statistically different 
from that of toxin control-group (Groups 4 or 7) in Students /-test are 
indicated by #(P< 0.05). 
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3.1.5 Effects of AP on COX-2 
A. Modulation of COX-2 enzyme activity 
The result of COX-2 enzyme activity assay was shown in Figure 
3.21. When rats were treated with AP alone (Group 2), a significant 
decrease in the COX-2 activity was observed. In the co-treatment groups, 
toxin (DEN-CCU) caused a significant increase in COX-2 activity. The 
effect of DEN-CCU was depressed by the concurrent treatment of AP. The 
enzyme activity showed no apparent difference compared with the 
vehicle-control. However, in the AP post-treated rats, the significantly 
increased enzyme activity of COX-2 was not influenced by the 
post-treatment of AP. 
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Figure 3.21 Effects of AP on COX-2 activity. All data were expressed as mean 士 SD (« 二 
5-6). Values statistically different from that of vehicle control group (Groups 1，3，or 6) in 
Student's f test are indicated by * (P < 0.05). Values statistically different from that of 
toxin control group (Groups 4 or 7) in Student's /-test are indicated by 0.05). 
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B. Effects of AP on transcriptional level of COX-2 
RT-PCR further demonstrated the presence of COX-2 in the process of 
hepatocarcinogenesis. Figure 3.22 shows the transcripts encoding COX-2 
mRNA and yg-actin mRNA from the representatives of each group. In order 
to eliminate variation arising from technical procedures, the level of the 
transcripts was normalized against that of the constitutively expressed 
house-keeping yS-actin mRNA in the same sample and expressed as a ratio 
(Figure 3.22). The ratio from each vehicle-control was set as 1 for 
comparison. 
There was no significant difference between the AP-alone treatment 
group (Group 2) and its vehicle-control group (Group 1). Similarly, no 
varying extent was found in the three post-treatment groups (Groups 6, 7 
and 8). These inconsistent results with the enzyme activity assay indicate 
that there could be different modulating effects of AP on COX-2 enzyme 
and its transcription. 
In the co-treatment groups, however, DEN-CCU increased the 
expression of COX-2 mRNA as it did in the enzyme activity, while 
co-treatment with AP also produced a significant reduction on the induced 
expression by DEN-CCU exposure. 
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Fig旗 3.22 (A) COX.2 expression detected by RT-PCR. One representative sample 
一 each experimental group was demonstrated. (B) COX-2 expression level as 
a e — a t e d by COX-2: /.-actin ratio. The ratio of vehicle control was set as 1. All data 
. e r e expressed as mean 士 SD (« = 5-6). Values statistically different from that of vehicle 
control .roup (Groups 1, 3，or 6) in Student. Mest are indicated by * (P < 0.05, Values 
statistically different from that of toxin control group (Groups 4 or 7) in Student's Mest 
are indicated by 0.05). 
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3.1.6 Effects of AP on phase I and phase II enzymes 
A. Microsomal CYP2E1 assay 
As shown in Figure 3.23, the microsomal CYP2E1 activity towards 
；7-nitrophenol was induced by AP-alone treatment (Group 2). In the 
co-treatment groups, toxin (DEN-CCI4) treatment caused a significant 
increase in CYP2E1 activity (Group 4), while AP administration along with 
toxin-treatment (Group 5) depressed such an induction. 
In the post-treatment groups, the CYP2E1 activity was down-regulated 
after toxin (DEN-CCI4) treatment (Group 7), which was contrary to what 
was observed in the co-treatment groups. AP administration after toxin 
treatment slightly prevented such an inhibition though the effect was not 
significant {P < 0.07). 
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Figure 3.23 Effects of AP on microsomal CYP2E1 activity. All data were expressed as 
mean 士 SD (w = 5-6). Values statistically different from that of vehicle control group 
(Groups 1，3，or 6) in Student's /-test are indicated by * (P < 0.05). Values statistically 
different from that of toxin control group (Groups 4 or 7) in Student's ftest are 
indicated by #(P< 0.05). 
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B. GST enzyme assay 
Effects of AP treatment on total GST activity in rat liver were 
demonstrated in Figure 3.24. In general, AP treatment induced the total 
GST activity in rats when administrated either alone (Group 2) or in 
addition to toxin (DEN-CCI4) treatment (Groups 5 and 8). 
In the co-treatment groups, toxin (DEN-CCI4) treatment (Group 4) 
caused a slight decrease in enzyme activity. This was subsequently retrieved 
by the concurrent treatment of AP (Group 5). In the post-treatment groups, 
the total GST activity was slightly induced instead (Group 7), while AP 
administration after toxin treatment significantly induced the GST activity 
again (Group 8). It was noticeable that the slight difference between 
toxin-controls (Groups 4 and 7) and their vehicle-controls (Groups 3 and 6) 
was not significant. 
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Figure 3.24 Effects of AP on total GST enzyme activity. All data were expressed as mean 
土 SD (« = 5-6). Values statistically different from that of vehicle-control group (Groups 1， 
3，or 6) in Student's t-test are indicated by * (P < 0.05). Values statistically different from 
that of toxin control group (Groups 4 or 7) in Student's ,-test are indicated by < 
0.05). 
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3.2 In vitro study 
3.2.1 Effects of AP on proliferation of H4nE cells detected by 
Neutral Red Assay 
The cytotoxicity effect of the water extract of AP was assessed by a 
cell growth inhibition assay using the H4IIE cell line. The growth of cells in 
the presence of various concentrations of AP was examined. For 
comparison, a normal cell line from rat liver, Clone 9 was adopted to show 
the selective effects of AP towards normal cell and cancer cell. 
Under the experimental conditions (5 days' continuous exposure), AP 
exhibited a marked growth inhibitory effect in a dose-dependant maimer at 
the end of 5-day incubation. The effective dosage at 50% reduction of the 
activity of AP (IC50) was about 1.1 mg/mL for H4IIE cell and above 2.0 
mg/mL for Clone 9 cell, respectively (Figure 3.25). 
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Figure 3.25 Neutral red assay for cytotoxicity study of AP 
on H4IIE. Clone 9 was used for comparison. 
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3.2.2 Assessment of cell cycle distribution by flow cytometry 
To study the mode of action of antiproliferative effect of AP, the 
variations of cell cycle profile upon treatment of H4IIE cells with different 
concentrations of AP were investigated. The DNA histograms obtained 
indicate that treatment with < 0.4 mg/mL AP showed no marked effect on 
the cell cycle distribution. However, at the AP concentration of 0.8 mg/mL, 
where the cell viability was above 50% during the test period (5 days), the 
accumulation of the cells in the G2/M phase occurred as early as 1.5 hours. 
More cells were arrested along with the increase of AP concentration to 1.6 
mg/mL, and the accumulation seems to exhibit in a time-dependent manner 
at this concentration. Nevertheless, there was no observation ofsubGl peak 
in the histograms, which is usually an indication of apoptosis. The results 
suggest that either a fraction of cells were arrested in G2/M or the 
progression of all cells through G2/M phase was slowed. (Figures 3.26, 
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Figure 3.26 DNA histograms demonstrating the attribution of H4IIE cells in cell cycle 
after incubation with AP for 1.5 h. (A) AP concentration was 0 mg/mL. (B) AP 
concentration was 0.4 mg/mL. (C) AP concentration was 0.8 mg/mL. (D) AP 
concentration was 1.6 mg/mL. 
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Figure 3.27 DNA histograms demonstrating the attribution of H4IIE cells in cell cycle 
after incubation with AP for 24 h. (A) AP concentration was 0 mg/mL. (B) AP 
concentration was 0.4 mg/mL. (C) AP concentration was 0.8 mg/mL. (D) AP 
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Figure 3.28 DNA histograms demonstrating the attribution of H4IIE cells in cell cycle 
after incubation with AP for 48 h. (A) AP concentration was 0 mg/mL. (B) AP 
concentration was 0.4 mg/mL. (C) AP concentration was 0.8 mg/mL. (D) AP 
concentration was 1.6 mg/mL. 
85 
1 k B 
M i s 丨 s 
I * :G2/M| *G2/M 
1 • "jjii丨 j 』 i —— 




1 D C 
J ^ 
‘ :G2M I I 111. 
A . . L u w ^ . i i l i iwi i ^ 
— 11 如“_丨丨 | | 丨 _ 丨 | 丨 ^^ “ 晰 
‘ ‘ Empty 
Figure 3.29 DNA histograms demonstrating the attribution of H4IIE cells in cell cycle 
after incubation with AP for 72 h. (A) AP concentration was 0 mg/mL. (B) AP 
concentration was 0.4 mg/mL. (C) AP concentration was 0.8 mg/mL. (D) AP 
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Figure 3.30 Cell distributions in different phases of cell cycle after 
AP treatment at different concentration for different exposure 
period. 
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3.2.3 DNA Fragmentation Assay 
An important feature of cell death is the fragmentation of genomic 
DNA into integer multiples of 180-bp units producing a characteristic 
ladder on agarose gel electrophoresis, which is due to the cleavage of DNA 
at the linker between nucleosomes (Reed J.C., 2000). 
In this experiment, after incubation with different concentrations of AP 
for 2 hours, 24 hours and 96 hours, respectively, no typical ladder pattern 
was observed (Figure 3.31). The result indicates that AP did not induce 
apoptosis in H4IIE cells under tested conditions. 
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Figure 3.31 DNA electrophoresis gel for detection of DNA 
laddering. There was no noticeable DNA ladder formed under 
tested AP-treatment conditions. 
89 
Chapter 4 Discussion 
4.1 In vivo study 
Male Fischer 344 rat was adopted as an animal model to investigate 
the initiation and promotion stages during the hepatocarcinogenesis process. • 
Hepatocellular carcinoma can be induced in the livers of laboratory animals 
by a variety of chemicals (Ha W.S. et al.，2001). It was reported that 
hepatoma could be induced by the administration of diethylnitrosamine 
(DEN) in combination with CCI4 (Kovalszky I. et aL, 1992). The chemicals 
are able to induce hepatoma within a short time and can be administered 
through different routes. 
4.1.1 Morphological changes during the induction of 
hepatocarcinogenesis 
In current study, the gross morphological observation and microscopic 
detection on hematoxylin and eosin staining (H & E) staining specimens 
indicated pathological changes caused by chronic liver damage after 
DEN-CCU administration. The hardness and shrinkage in liver size and the 
presence of fibrous septa with dissecting nodules, suggest a progression of 
fibrosis. The nodularity in the liver could be most probably due to fibrosis 
dissecting the parenchyma in nodules. The liver possesses a remarkable 
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regenerative capacity. Regenerative nodules may form in the fibrous septa. 
However, i f the damage affects the reticular framework, the repair w i l l 
occur by scar formation (fibrosis) that may lead to rearrangement of the 
blood circulation and to cirrhosis, and even further neoplastic 
transformation. (Emilio Orfei et al., in progress) . 
The current observation indicates AP administration could protect the 
liver from DEN-CCU-induced abnormal changes to some extent. The 
protective effects of AP may contribute to the prevention of 
hepatocarcinogenesis. However, such observations did not quantify the 
degree of liver damage. The qualitative observations do not take into 
consideration any parameter regarding the fibrosis because they do not 
provide numerical data (Gaudio E. et al.’ 1993). It provides only a crude 
‘ estimation. 
4.1.2 Effects of AP on GST-P foci and its mRNA 
To further assess the anti-carcinogenic effects of AP, the classical 
preneoplastic marker enzyme for hepatic chemical carcinogenesis, GST-P 
was monitored. This class of GST is ubiquitously distributed, but is found 
only in relatively small amounts in normal rat liver (Sato K., 1989). Its 
altered expression has been linked to carcinogenesis and tumor progression 
(Satoh K. et al； 1985). In rats, the earliest stages of hepatocarcinogenesis 
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are characterized by a dramatic increase in the expression of GST-P gene. 
Administration of a single dose of a genotoxic hepatocarcinogen leading to 
the development of hepatic preneoplastic nodules was reported to produce a 
rapid and large increase in the levels of GST-P in the liver that persists until 
hepatocellular carcinoma development (Kitahara A. et al., 1984; Meyer D.J. 
et al； 1985; Jensson H. et al., 1985; Suguoka Y. et al., 1985; Sugioka Y. et 
al； 1985) 
The results from the immunohistochemical study demonstrated a 
protective effect of AP on liver by reducing GST-P positive foci in both the 
co-treatment group (77.8%) and post-treatment group (36.9%), respectively 
(Table 3.2). 
GST-P is considered to be a stable marker for persistent preneoplastic 
and neoplastic cells not only at the protein level, but also at the mRNA level 
throughout hepatocarcinogenesis in rats (Imai T. et al., 1997). The effect of 
AP on the DEN-CCU-induced hepatocarcinogenesis was also detected as 
evidenced by the expression of transcription of GST-P mRNA. The RT-PCR 
result indicates that AP could reduce GST-P mRNA expression caused by 
DEN-CCU in the percentage of 29.9% in co-treatment and 16.4% in 
post-treatment, respectively (Figure 3.20). 
As the appearance of GST-P positive foci and the induction of GST-P 
92 
mRNA can be correlated with the development of hepatocellular carcinoma, 
the effectiveness of AP in preventing altered foci formation as well as gene 
expression provides unequivocal evidence to show that AP is capable of 
protecting rats from DEN-CCU-induced hepatocarcinogenesis. However, 
although the anti-carcinogenic effects of AP were revealed in both the 
co-treatment and post-treatment groups, the relative lower reduction of 
GST-P foci in the AP-post-treated rats indicates that AP could exhibit 
anti-cancer effects more efficiently in the early initiation and promotion 
stages of hepatocarcinogenesis rather than in the post-promotion stage. 
4.1.3 Effects of AP on COX-2 enzyme activity and mRNA 
expression 
Cyclooxygenase-2 (COX-2) is a key enzyme responsible for the 
synthesis of inflammatory prostaglandins from arachidonic acid. It is 
known to be responsible for inflammatory reaction and carcinogenesis of 
hepatocellular carcinoma (Koga H. et al., 1999; Shiota G. et al., 1999; K im 
S.H. et al., 2002). The over-expressed COX-2 causes liver injury by 
induced synthesis of PG (Nanji A.A. et al., 1997). Elevated COX-2 gene 
expression was associated with several types of carcinogenesis (DeWitt, D. 
et al., 1995; Sano H. et al., 1995; Muller-Decker K. et al., 1995). COX-2 is 
supposed to be involved in the early stage of hepatocarcinogenesis 
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associated with fatty change, fibrosis and cirrhosis and contributes to tumor 
formation or growth, though the in vivo mechanism by which it affects 
tumor growth has not been determined (Denda A ” et al., 2002; Kondo M. et 
al； 1999; Bae S.H. et al., 2001; Cuendet M. et al., 2000). 
The up-regulation of COX-2 activity in toxin-control groups (Groups 4 
and 7) and mRNA expression in co-treatment toxin-control group (Group 4) 
is consistent with previous reports that COX-2 expression can be induced 
by carcinogens (DuBois R.N. et al., 1996; Ledwith B.J. et al； 1997; Kelley 
DJ . et al., 1997). It was suggested that the up-regulation of COX-2 of 
non-tumor cirrhotic liver tissues might be closely related to the active 
inflammation (Bae S.H. et al., 2001). One possible explanation for the little 
change in mRNA expression in the toxin control group of post-treatment 
(Group 7), however, may be the degradation happened in the prolonged 
feeding period (10 weeks) in view of the fact that COX-2 mRNA contains 
multiple AUUUA motifs in its 3,-untranslated region consistent with rapid 
mRNA degradation (Kujubu,D.A. et al., 1991). 
The observation that both AP-alone treatment (Group 2) and AP 
co-treatment with toxin (Group 5) exhibited lower COX-2 activity than 
corresponding control (Group 1 and 4) suggest that AP may contain 
components as a potential inhibitor of COX-2. Since the AP-post-treated 
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rats (Group 8) were hardly affected, AP may exhibit its effects probably 
through regulating the events that were related to the bioactivation of 
COX-2. AP could only affect the elevated mRNA expression but not basal 
COX-2 expression on transcriptional level, since no significant change was 
noted in Group 2 and Group 8. 
4.1.4 Modulation effects of AP on CYP2E1 and GST enzyme 
activity 
The cytochrome P-450 (CYP) and glutathione ^'-transferase (GST) 
enzyme systems may influence the biological effects of carcinogens, 
including DEN and CCI4. Carcinogen-metabolizing enzymes may be targets 
for chemoprevention. CYP2E1 and GST are believed to be the phase I and 
phase I I enzymes contribute to the metabolic activation and detoxification 
of the administrated DEN-CCI4, respectively. 
CYP2E1 is involved in the bioactivation of many small hepatotoxic 
and carcinogenic compounds, including DEN (Vema L. et al” 1996), CCI4， 
and CHCI3 (Johansson I. et aL, 1985; English J.C. et al； 1985; Guengerich 
F.P. et al” 1991; Raucy J.L. et al.，1993). It is known as a heme-containing 
enzyme that produces abundant free radicals, and its involvement in 
carcinogenesis has been suggested in several organs in vivo (Hirose Y. et al” 
2002).The activity of CYP2E1 towards j^-nitrophenol seems to change in 
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the feeding period as compared with the control: it was up-regulated at the 
end of 5 weeks (Group 4) but down-regulated at the end of 10 weeks 
(Group 7). The change may result from the different molecular events 
involved during the process of multi-stage hepatocarcinogenesis. However, 
AP treatments in both the co-treated rats and the post-treated rats seem to be 
able to retain CYP2E1 activity in a normal condition. In co-treatment 
groups, the inhibition of up-regulated activity by AP may contribute to the 
prevention of bioactivation of procarcinogens by CYP2E1. In 
post-treatment groups, the elevated activity of CYP2E1 by AP, though not 
statistically significant, may represent for a retrieve of consumed enzyme 
content during the metabolism process. 
Glutathione S-transferases (GSTs) represent a major group of 
detoxification enzymes that play critical roles in eliminating electrophiles 
and products of oxidative stress. It is widely accepted that the induction of 
phase I I enzymes such as GST could contribute to the protection of the liver 
against toxicity and chemical carcinogenesis (Hayes J.D. et aL, 1995). 
In present study, the total GST activity in DEN-CCU treated rats was 
induced by AP administration in both the co-treated and post-treated groups 
(Group 5 and 8), which suggests a marked protective effect of AP on rat 
liver during hepatocarcinogenesis. 
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It is noticed that AP-alone treatment (Group 2) could induce both the 
CYP2E1 and total GST activity, when compared with the vehicle-control 
(Group 1). There might be two possibilities for this case. One possibility is 
the water extract of AP may contain component as bifunctional inducer, i.e., 
components which can induce both phase I and phase I I enzymes (Prestera 
T. et al, 1993). I f this is the case, it is supposed that metabolism of the 
parental compound of the component is required for induction of phase I I 
enzymes by CYP enzymes (Hayes J.D. et al； 1995). The other possibility is 
that the extract might contain components acting as inducers for phase I and 
phase I I enzymes, respectively. In this case, it would be advantageous i f the 
component as the monofunctional inducer for phase I I enzyme (e.g. GST) 
could be figured out, since the inducer for phase I enzyme (e.g. CYP2E1) 
usually contributes to the activation of carcinogens (Vema L. et al., 1996). 
4.2 In vitro study: effects of AP on cancer cell proliferation 
The hepatoma cell line was used to detect the anti-cancer effects of AP 
extract on the proliferation of cancer cells, which could be considered as the 
progression stage in the heptocarcinogenesis process. The present study 
demonstrated that AP possesses growth-inhibitory capability against the 
hepatoma cell line H4IIE. 
In mammalian cells, genotoxic stress can be followed by a secondary 
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response of either growth arrest or apoptosis (Wang J.Y. et al, 2001), i.e., 
by evoking cell cycle arrest to elicit D N A repair systems or by eliminating 
damaged cells through induction of apoptosis. Genotoxic stress w i l l induce 
a sustained arrest that can be distinguished from the cell-cycle checkpoints. 
Each checkpoint is involved in temporary arrest in a specific stage of the 
cell cycle to allow the cell to correct any defects (Elledge SJ.，1996). The 
accumulation of cells in a certain phase can be detected by flow cytometry. 
In apoptosis, cells die in a controlled and regulated fashion by fragmenting 
into small membrane-bound bodies with intact organelles and plasma 
membrane (Rust C. et al•，2000). Ordered D N A fragmentation is a 
biochemical characteristic of apoptosis, which can be demonstrated by the 
classical ladder pattern found in DNA electrophoresis gel or subdiploid 
DNA content in flow cytometry analysis. 
Our findings indicate the anti-cancer effects of AP could be attributed 
to the cell cycle arrest, but not cancer cell apoptosis under our experimental 
conditions, since no subGl phase peak or DNA fragmentation was detected 
in the cells with AP treatment at various concentrations and for different 
periods of time (Figures 3.29 and 3.31). As evidenced by flow cytometry 
analysis，cell growth inhibition could be attributed to the accumulation of 
the cells in the G2/M phase, in the presence of AP with concentrations 
ranging from 0.8 mg/mL to 1.6 mg/mL. 
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4.3 Summary 
The present results are consistent with previous studies that AP 
exhibits anti-tumor effects on transplantable rodent tumors (Tang et al； 
1981)，and have verified the benefits of AP in anti-cancer prescriptions. The 
anti-cancer ability of AP was demonstrated mainly in vivo by the significant ^ 
inhibition of GST-P foci formulation in DEN - C C I 4 treated rats, and in vitro 
by the anti-proliferation effects on a hepatoma cell line H4IIE. 
The results suggest that the biologic activity of AP may involve 
inhibiting the elevated COX-2 in the early stages of hepatocarcinogenesis; 
modulating specific phase I and phase I I enzymes that activate and detoxify 
the carcinogens; arresting the cancer cell proliferation at G2/M phase. 
Liver is a vital organ for the metabolism and detoxification of 
xenobiotics (M. Murray, 1994). In case of hepato-poisoning, the liver may 
lose its normal functions and in turn make the body predisposed to 
carcinogenesis. In the present study, our results from morphological 
observation and enzymes assays indicate AP displayed some curative 
effects on DEN-CCU-intoxicated livers, suggesting its potential to restore 
liver functions and play an essential role in detoxmcation of xenobiotics. 
The in vivo studies suggested that AP exhibited anti-cancer activity in 
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both the initiation-promotion and post-promotion stages, though better 
protection could be achieved when AP was administered as early as the 
initiation began. This is reasonable when considering that cancer is 
ultimately the end stage of a chronic disease process characterized by 
abnormal cell and tissue differentiation, and it is easier to fix anything when 
the smallest changes happen (Spom M.B. et al” 2000). 
Previous study found that agrimoniin, a component of AP, is a potent 
anti-tumor tannin and suggested that the anti-tumor effect may be due to 
this tannin enhancing the immune response of the host animals through the 
actions on tumor cells and some immunocytes (Miyamoto K. et al； 1987; 
Miyamoto K. et al., 1988; Murayama T. et al； 1992). It was found in our 
study that AP could modulate COX-2, which is known to be responsible for 
inflammatory reaction and carcinogenesis of hepatocellular carcinoma. 
Thus，it is believed that regulation of the immune system could contribute 
in part to the prevention of hepatocarcinogenesis. 
It remains unclear what component(s) of Agrimonia Pilosa Ledeb. 
might contribute to cancer chemopreventive potential. Among a variety of 
AP ingredients, agrimoniin is a potential ingredient as it has been shown to 
inhibit tumor progression in tumor-transplanted mice (Miyamoto K. et al., 
1987). By examining effects of different fractions of extract, the active 
100 
constituents can be identified. Such investigations are necessary to define 
future strategy for the use of AP as a cancer chemopreventive. 
The current study demonstrated the anti-cancer effects of AP in 
hepatocarcinogenesis and discussed some of its biologic activity that may 
be involved. However, it is difficult to conclude from our limited 
experiments the active components that contribute to the anti-cancer ability 
of AP. More investigations are needed to understand its mode of action. 
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